NEW YORK (GenomeWeb News) – UBS today said it has downgraded Bruker BioSciences’ stock to “Neutral" from "Buy."
 
According to Reuters, the brokerage said Bruker’s Daltonics division “faces increasing competition from much larger mass spectrometry vendors, potentially limiting upside.”
 
UBS maintained its $7 price target on Bruker’s stock, Reuters said.
 
The stock was down 1.62 percent, or $.10, at 6.04 in mid-afternoon trading today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.